Evidence map›Paper›PMID 33072177›Full record

ArticleNano today2020

Biomimetic fibrin-targeted and H

Yi Zhao, Ruosen Xie, Nisakorn Yodsanit, Mingzhou Ye, Yuyuan Wang, Shaoqin Gong

Open access · greenAbstract read
In one paragraph

Article in Nano today, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 116 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yi ZhaoWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.
Ruosen XieWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.
Nisakorn YodsanitWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.
Mingzhou YeWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.
Yuyuan WangWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.
Shaoqin GongWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.
Wisconsin Institutes for Discovery · USUniversity of Wisconsin–Madison · US

Funding

Targeting PERK: An Endothelium-Protective Stent-Free Strategy for Mitigation of Intimal Hyperplasia After Vascular SurgeryR01HL143469 · NHLBI · UNIVERSITY OF VIRGINIA · PI GONG, SHAOQIN -, GUO, LIANWANG · 2018 to 2021
$2.4M
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstructionR01HL129785 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GUO, LIANWANG, KENT, K CRAIG · 2016 to 2019
$2.0M
NHLBI NIH HHS R01 HL129785NHLBI NIH HHS R01 HL143469
6 · The paper itself

Abstract

Thrombosis is a principle cause of various life-threatening cardiovascular diseases. However, current antithrombotic treatments using drugs only offer limited efficacy due to short half-life, low targeting ability to the thrombus site, and unexpected bleeding complications. Taking into account of the biological characteristics of thrombus including upregulation of hydrogen peroxide (H

Identifiers

PMID33072177
PMCPMC7561002
OpenAlexW3090722419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.